PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors
Antitumor activity of PF-06952229 was observed in preclinical studies. PF-06952229 was generally well tolerated with manageable toxicity; a small group of patients achieved durable responses and/or disease stabilization.
Authors
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- L. Zhang
- Kayla L. Stratton (ORCID: https://orcid.org/0000-0002-5201-4565)
- Lee S. Rosen (ORCID: https://orcid.org/0000-0003-2503-6133)
- A. W. Tolcher
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Atish D. Choudhury (ORCID: https://orcid.org/0000-0001-9344-6631)
- David Schaer (ORCID: https://orcid.org/0000-0003-1570-7722)
- Rajendar K. Mittapalli (ORCID: https://orcid.org/0000-0001-7738-4039)
- M. Gordon
- Lei Liu (ORCID: https://orcid.org/0000-0002-3630-3674)
- Wei Zhong (ORCID: https://orcid.org/0000-0001-8854-566X)
- N. Soman
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Sarah Cannon Research Institute (GB)
- Pfizer (United States) (US)
- Dana-Farber Cancer Institute (US)
- HonorHealth (US)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103653
- Citations
- 13
- Primary Topic
- TGF-β signaling in diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Celgene
- FibroGen
- Endocyte
- Jazz Pharmaceuticals
- Celldex Therapeutics
- Clovis Oncology
- Myriad Genetics
- BeiGene
- Incyte
- Syndax Pharmaceuticals
- Revolution Medicines
- Ascentage Pharma
- Seagen
- Y-mAbs Therapeutics
- Astellas Pharma
- Toray Industries
- Sun Pharma
- Plexxikon
- Genentech
- EMD Serono
- Daiichi Sankyo Europe